English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew research presented during the 2024 San Antonio Breast Cancer Symposium (SABCS) reveals a new machine learning model that could change the way metastatic breast cancer is treated in the future. By combining clinical and genomic data, physician-scientists from Memorial Sloan Kettering Cancer Center (MSK) developed a tool that could help improve predictions of how people with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer respond to CDK4/6 inhibitors, a class of oral medications that control cell division and are often prescribed in combination with hormone therapy to treat this subset of patients.
Tag: Hormone Therapy
Menopause is having a moment: Debunking common myths
Many women approach menopause with anxiety about the future. You’ve probably heard about it being a stressful time full of hot flashes, weight gain, and plummeting sex drive. The good news? Menopause is having a moment. That means heightened awareness, more resources dedicated to improving women’s health, and open discussions to ensure you get the information you need.
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Understanding of mechanisms behind post-exercise lack of appetite can open new paths to obesity treatment
The complex relationship between physical activity and energy balance – food intake versus energy expenditure – is still a challenge for science, especially in light of the rising worldwide prevalence of overweight and obesity.
Single hospital study finds transgender teenagers rarely choose to discontinue hormone therapy
A three-year-long retrospective cohort study of a single Atlanta hospital’s patient population found transgender and gender-diverse teenagers rarely chose to discontinue gender-affirming hormone therapy, according to a study being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Transgender people seen in the ER much more likely than cisgender people to be admitted to hospital
Transgender people who come to the emergency room for care tend to be sicker than cisgender people who are otherwise similar to them and are much more likely to be admitted to the hospital once they visit the ER, according to a study being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Women taking oral estrogen hormones may have increased risk of high blood pressure
Women ages 45 years and older taking estrogen hormone therapy in pill form were more likely to develop high blood pressure than those using transdermal (topical, applied to the skin) or vaginal formulations, according to new research published today in Hypertension, a peer-reviewed American Heart Association journal.
New treatment can improve cardiac pump function in patients with heart failure
A clinical study by researchers at Karolinska Institutet and Karolinska University Hospital in Sweden shows that the hunger hormone ghrelin can increase the heart’s pump capacity in patients with heart failure.
Kisspeptin hormone injection could treat low sex drive in women and men
The hormone kisspeptin could be used to treat women and men distressed by their low sexual desire, according to two new studies.
Menopause symptoms: Mayo Clinic expert outlines hormone and nonhormonal therapies
Menopause, the end of menstrual cycles, can produce symptoms such as hot flashes, night sweats, insomnia and mood changes. Women do not need to suffer in silence: Many treatment options are available. Jewel Kling, M.D., chair of the Division of Women’s Health at Mayo Clinic in Scottsdale, Arizona, describes hormonal and nonhormonal therapies.
Scientists identify multiple cell types that may contribute to treatment resistance in prostate cancer
Researchers have characterised prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour no longer responds to hormone deprivation therapy.
Hormone therapy could lower risk of immunotherapy-associated myocarditis in women
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
Hormone therapy experiences vary by race among women in menopause
While hormone therapy was associated with higher self-reported quality of life in white women, Black women actually experienced lower overall quality of life under the same treatment.
Study suggests commonly used prostate cancer treatment rewires engine of prostate tumors
A new study from the University of Michigan Rogel Cancer Center suggests androgen receptor inhibitors can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. These findings will be published in Nature Communications on Sept. 15.
Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease
Hormone therapy for prostate cancer increases the risk of cardiovascular disease-related death especially in older men, according to a population study involving more than 13,000 patients.
Genetic biomarker test predicts recurrence and survival outcomes for men with high-risk prostate cancer
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
New Potential Therapy for Fatty Liver Disease
In a subset of patients with partial lipodystrophy and/or NASH, the hormone leptin can be leveraged as a therapeutic agent to move fat out of the liver.
Researchers aim to modify fragmented health care system to reduce HIV incidence among trans women
There are an estimated one-million transgender adults living in the U.S. and an estimated 14% of transgender women are living with HIV. Researchers at UTHealth are studying if a combination intervention that combines HIV prevention services and hormonal therapy, supported by peer health navigation, will reduce HIV acquisition among this patient population.
Imaging identifies breast cancer patients unlikely to benefit from hormone therapy
Hormone therapy can be effective for receptor-positive breast cancer, but it only works for 55% of patients. Researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to a one-day estrogen challenge benefited from hormone therapy. The findings could help improve treatment decisions.
Phase 1 human trials suggest UIC-developed breast cancer drug is safe, effective
A new type of breast cancer drug can help halt progression of disease and is not toxic, according to phase 1 clinical trials.